Walvax Biotech Announces Positive Safety and Immunogenicity Results from Phase II Sequential Booster Trials of Its mRNA COVID-19 Vaccine Developed with Abogen Biosciences

Walvax Biotechnology Co., Ltd. announced on December 28 in an interactive platform that the results of the sequential booster immunization clinical studies conducted in Guangxi and Yunnan provinces in China for the COVID-19 mRNA vaccine jointly developed with Abogen Biosciences showed good safety and immunogenicity. The results of the Yunnan sequential study have been published in the international journal *Cell Research*.